ACADIA Pharmaceuticals enters the week of its earnings release with short interest at a four-month high — up 25% in just one month — yet the borrow market remains so loose it barely registers as friction.
The positioning shift is the story this week. Short interest has climbed steadily to 6.3% of the free float, adding more than 2.1 million shares since early April. The surge began around April 9–10 and has not reversed. At the last official FINRA fortnightly settlement (April 15), shorts were running 7.4 days to cover. That's a meaningful rebuild. Yet the lending market tells a very different story: cost to borrow has fallen sharply to just 0.33%, down more than 32% on the week and 35% over the past month, while availability remains extremely loose. In practical terms, anyone wanting to add a short position faces almost no friction in the borrow market — shares are plentiful and cheap to rent.
The options market corroborates that lack of urgency. The put/call ratio at 0.54 is essentially flat against its 20-day average of the same level, with a z-score near zero. That's a neutral read — no meaningful tilt toward downside protection, and no surge in call buying either. The 52-week range on the PCR spans 0.14 to 1.02, so this reading is squarely in the middle. Taken together, positioning looks active on the short side but unencumbered — shorts are rebuilding without needing to fight for inventory, and options traders are not adding directional bets on top.
The Street remains broadly constructive, though the last wave of analyst activity — concentrated around the February earnings print — reflected a mixed picture. B of A Securities upgraded to Buy in late March, keeping its $29 target. JP Morgan lifted its target to $34 at the start of March while holding Overweight. TD Cowen and Citizens both raised targets, while RBC trimmed to $30 and Stifel held a cautious Hold at $24. The mean price target sits near $31.70, roughly 42% above the current $22.35 price. Bulls point to the commercial momentum behind NUPLAZID and DAYBUE, with a new STIX formulation in the pipeline as a potential near-term catalyst. Bears flag the early-stage nature of the broader pipeline, competitive pressure in the rare disease space, and execution risk around peak revenue estimates. The P/E multiple has eased to about 34.6x, down nearly 2.8x over the past 30 days, while EV/EBITDA has pulled in to around 24.7x — a modest de-rating. The EPS surprise factor score ranks in the 98th percentile, a standout in an otherwise middling factor profile.
Institutional ownership adds a layer of structural support. Baker Bros. Advisors holds nearly 25% of shares and trimmed only modestly at its last report. BlackRock and State Street both added in their most recent filings — the former adding 487,000 shares, the latter more than 655,000. That's a firm foundation of sticky institutional capital. Insider activity, by contrast, is routine: the CFO and principal accounting officer both sold small amounts in early May after receiving awards, all at low significance scores. Nothing there changes the picture.
The next scheduled earnings event is May 29. With short interest at its highest since early April, borrow costs at a one-month low, and options traders holding steady, the setup heading into that print will be worth watching closely — particularly whether the short rebuilding continues or begins to unwind ahead of the release.
See the live data behind this article on ORTEX.
Open ACAD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
